Home / Market News / $TXG

$TXG news and market catalysts

The 25 most recent market catalysts affecting $TXG, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

25 catalysts 4 high impact 14 bullish 3 bearish Biotechnology
Nov 16, 2026 Corporate Catalyst Bullish Impact 55
10x Genomics Announces New Research Collaborations for Autoimmune Disease Diagnostics
10x Genomics announced new research collaborations with Charité – Universitätsmedizin Berlin, DRFZ, and Seoul National University. These partnerships will utilize 10x Genomics' Fle…
Nov 11, 2026 Corporate Catalyst Neutral Impact 55
Stephens Initiates Coverage on 10x Genomics with Hold Rating
Stephens analyst Mason Carrico initiated coverage on 10x Genomics (TXG) with a 'Hold' rating and set a price target of $65. This event is significant as new analyst coverage can br…
Nov 6, 2026 Corporate Catalyst Neutral Impact 65
Analysts Update Price Targets for 10x Genomics Following Q3 Earnings
Following 10x Genomics' Q3 2026 earnings, Deutsche Bank and UBS both lowered their price targets, while Stifel increased its target. This mixed reaction from analysts suggests that…
Nov 6, 2026 Corporate Catalyst Bullish Impact 65
Stifel Maintains Buy Rating and Raises Price Target for 10x Genomics
Stifel, a prominent financial services firm, has raised its price target for 10x Genomics (TXG) from $50 to $68, representing a substantial 36% increase. This upward revision, coup…
Nov 5, 2026 Corporate Catalyst Bullish Impact 85
10x Genomics Reports Q3 2026 Financial Results and Raises Full-Year Revenue Guidance
10x Genomics announced Q3 2026 results that surpassed analyst expectations for both revenue and earnings, while also showing improved profitability metrics like narrower operating …
Nov 5, 2026 Corporate Catalyst Neutral Impact 92
Torex Gold Resources Inc. Reports Q3 2026 Financial Results
Torex Gold Resources Inc. disclosed its Q3 2026 financial results, reporting $555 million in revenue, $155.2 million in net income, and $150.4 million in free cash flow. These figu…
Oct 23, 2026 Corporate Catalyst Bearish Impact 65
Stephens Downgrades 10x Genomics to Equal Weight
Stephens, an investment firm, downgraded 10x Genomics (TXG) from an Overweight to an Equal Weight rating and established a $65 price target. This action signals a more conservative…
Oct 12, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100
Canaccord Genuity's analyst Kyle Mikson has maintained a 'Buy' rating on 10x Genomics (TXG) and raised the price target from $60 to $100. This is a significant upward revision, ind…
Oct 7, 2026 Corporate Catalyst Bullish Impact 65
Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $110
Barclays analyst Luke Sergott maintained an 'Overweight' rating on 10x Genomics (TXG) and more than doubled the price target from $52 to $110. This significant upgrade signals incr…
Sep 30, 2026 Corporate Catalyst Bullish Impact 75
10x Genomics shares are trading higher after the company launched its Sentira cloud-based spatial analysis tool and announced the first shipments of its Atera transcriptome analysis tool.
The launch of Sentira and Atera represents a significant corporate catalyst for 10x Genomics, directly impacting its stock positively due to anticipated revenue growth and enhanced…
Sep 29, 2026 Corporate Catalyst Bullish Impact 65
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90
Leerink Partners analyst Mike Kratky has significantly increased the price target for 10x Genomics (TXG) from $40 to $90. This substantial jump in the price target, while maintaini…
Sep 29, 2026 Corporate Catalyst Neutral Impact 65
10x Genomics Begins Commercial Shipments Of Its Transcriptome Analysis Tool Atera
10x Genomics announced the start of commercial shipments for its Atera transcriptome analysis tool. This is a significant milestone as it moves the product from pre-order status to…
Sep 29, 2026 Corporate Catalyst Neutral Impact 65
10x Genomics Launches NVIDIA-Accelerated Sentira Spatial Analysis, Cutting Spatial Data Processing Times From Hours To Minutes
10x Genomics (TXG) has launched Sentira Spatial Analysis, a new cloud-based platform designed to drastically cut spatial data processing times from hours to minutes by utilizing NV…
Sep 28, 2026 Corporate Catalyst Bullish Impact 75
10x Genomics shares are trading higher after Argus Research initiated coverage on the stock with a Buy rating and announced a $110 price target. Also, Piper Sandler maintained its Neutral rating and raised its price target from $47 to $80.
The primary impact of this headline is a positive catalyst for 10x Genomics (TXG). The initiation of coverage with a 'Buy' rating and a $110 price target from Argus Research, coupl…
Sep 28, 2026 Corporate Catalyst Neutral Impact 65
Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110
Argus Research has initiated coverage on 10x Genomics, assigning a 'Buy' rating and a $110 price target. This event is significant because new analyst coverage, especially with a p…
Sep 10, 2026 Corporate Catalyst Neutral Impact 55
10x Genomics To Incorporate Lunit's AI-Powered Pathology Platform Into Its Oncology Biomarker Discovery Workflow
This 8-K filing announces a collaboration where 10x Genomics will incorporate Lunit's AI pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. This is…
Sep 1, 2026 Corporate Catalyst Neutral Impact 60
RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70
RBC Capital's initiation of coverage on 10x Genomics (TXG) with a 'Sector Perform' rating and a $70 price target provides a new data point for investors. This event is significant …
Aug 31, 2026 Corporate Catalyst Bearish Impact 65
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit
10x Genomics (TXG) won a significant patent infringement lawsuit against Parse Biosciences, a subsidiary of Qiagen (QGEN), resulting in a $4.8 million damages award. This is a clea…
Aug 10, 2026 Corporate Catalyst Bullish Impact 75
10x Genomics shares are trading higher after Canaccord raised its price target on the stock from $50 to $60.
This headline indicates a significant positive corporate catalyst for 10x Genomics. An analyst upgrade, especially with a notable price target increase, often reflects improved fun…
Aug 10, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $60
Canaccord Genuity analyst Kyle Mikson has maintained a 'Buy' rating on 10x Genomics (TXG) and raised the price target from $50 to $60. This indicates a strengthened conviction from…
Aug 7, 2026 Corporate Catalyst Bullish Impact 92
Torex Gold Resources Q2 Adj. EPS $0.90 Misses $1.22 Estimate, Sales $406.900M Miss $420.000M Estimate
Torex Gold Resources (TXG) announced Q2 adjusted EPS of $0.90, missing the analyst consensus of $1.22 by 26.23%, and sales of $406.9 million, missing the $420 million estimate by 3…
Aug 6, 2026 Corporate Catalyst Bullish Impact 75
10x Genomics Raises FY2026 Sales Guidance from $600.000M-$625.000M to $610.000M-$630.000M vs $613.851M Est
10x Genomics (TXG) filed an 8-K to announce an upward revision to its fiscal year 2026 sales guidance. The company now expects sales to be between $610 million and $630 million, up…
Aug 6, 2026 Corporate Catalyst Bearish Impact 92
10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate
10x Genomics (TXG) announced Q2 results that showed a loss of $(0.14) per share, which was better than the $(0.24) estimate, and sales of $151.000 million, exceeding the $146.788 m…
Jul 17, 2026 Corporate Catalyst Bullish Impact 55
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $40
Leerink Partners analyst Mike Kratky has updated their coverage on 10x Genomics, maintaining a 'Market Perform' rating but notably raising the price target from $23 to $40. This ac…
Jul 14, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $50
Canaccord Genuity's analyst Kyle Mikson has maintained a 'Buy' rating on 10x Genomics (TXG) and significantly raised the price target from $32 to $50. This action signals increased…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.